PHARMING GROUP NV (PHARM.AS) Forecast, Price Target & Analyst Ratings
AMS:PHARM • NL0010391025
1.373 EUR
-0.02 (-1.29%)
Last: Mar 11, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMING GROUP NV (PHARM.AS).
Forecast Snapshot
Consensus Price Target
€2.19
+ 59.72% Upside
Next Earnings Forecast
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate$0.01
Revenue Estimate108.35M
ChartMill Buy Consensus
88.57%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
€2.19
Upside
+ 59.72%
From current price of €1.37 to mean target of €2.19, Based on 14 analyst forecasts
Low
€1.82
Median
€2.04
High
€2.73
Price Target Revisions
1 Month
0.00%
3 Months
9.14%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for PHARM.AS. The average price target is 2.19 EUR. This implies a price increase of 59.72% is expected in the next year compared to the current price of 1.373.
The average price target has been revised upward by 9.14% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
88.57%
PHARM.AS was analyzed by 14 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about PHARM.AS.
In the previous month the buy percentage consensus was at a similar level.
PHARM.AS was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate$0.01
Revenue Estimate108.35M
Revenue Q2Q16.92%
EPS Q2Q71.60%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
1.78%
Revenue (3 Months)
3.45%
EPS (1 Month)
-28.62%
EPS (3 Months)
0.00%
Next Earnings Summary
PHARM.AS is expected to report earnings on 3/12/2026. The consensus EPS estimate for the next earnings is 0.01 EUR and the consensus revenue estimate is 108.35M EUR.
The next earnings revenue estimate has been revised upward by 3.45% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 205.622M 3.39% | 245.316M 19.30% | 297.2M 21.15% | 380.19M 27.92% | 413.89M 8.86% | 425.05M 2.70% | 403.89M -4.98% | 488.21M 20.88% | 687.27M 40.77% | 485.44M -29.37% | |
| EBITDA YoY % growth | 23.555M -45.99% | -5.825M -124.73% | 12.476M 314.18% | 23.347M 87.14% | 25.209M 7.98% | 31.879M 26.46% | 78.826M 147.27% | 134.3M 70.38% | 235.66M 75.47% | N/A | |
| EBIT YoY % growth | 10.367M -56.80% | -21.75M -309.80% | -3.594M 83.48% | 17.986M 600.45% | 37.672M 109.45% | 44.036M 16.89% | 46.009M 4.48% | 84.367M 83.37% | 234.62M 178.09% | 42.453M -81.91% | |
| Operating Margin | 5.04% | -8.87% | -1.21% | 4.73% | 9.10% | 10.36% | 11.39% | 17.28% | 34.14% | 8.75% | |
| EPS YoY % growth | N/A 101.60% | -0.02 -132.92% | -0.02 -12.50% | -0.01 68.53% | 0.04 798.18% | 0.04 -6.77% | 0.06 66.48% | 0.12 88.42% | 0.22 94.12% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.01 71.60% | 0.00 100.00% | 0.02 243.33% | 0.01 3.00% | 0.01 20.05% |
| Revenue Q2Q % growth | 108.35M 16.92% | 95.79M 21.11% | 92.185M -1.09% | 89.61M -7.90% | 88.58M -18.25% |
| EBITDA Q2Q % growth | 11.433M -49.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 13.236M 97.55% | 3.09M 308.73% | 10.197M -21.25% | 7.21M -55.00% | 4.017M -69.65% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
59.38%
EPS Next 5 Year
53.15%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.00%
Revenue Next 5 Year
10.63%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
80.40%
EBIT Next 5 Year
78.86%
PHARMING GROUP NV / PHARM.AS Forecast FAQ
What is the average price target for PHARMING GROUP NV (PHARM.AS) stock?
14 analysts have analysed PHARM.AS and the average price target is 2.19 EUR. This implies a price increase of 59.72% is expected in the next year compared to the current price of 1.373.
What is the next earnings date for PHARM stock?
PHARMING GROUP NV (PHARM.AS) will report earnings on 2026-03-12, before the market open.
Can you provide the consensus estimates for PHARMING GROUP NV next earnings?
The consensus EPS estimate for the next earnings of PHARMING GROUP NV (PHARM.AS) is 0.01 EUR and the consensus revenue estimate is 108.35M EUR.
What is the consensus rating for PHARMING GROUP NV (PHARM.AS) stock?
The consensus rating for PHARMING GROUP NV (PHARM.AS) is 88.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.